Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GABRA1 | P14867 | 2/20 | 0.33 |
| ▸ | GABRB2 | P47870 | 2/20 | 0.33 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.33 |
| ▸ | LMNA | P02545 | 1/20 | 0.33 |
| ▸ | TP53 | P04637 | 1/20 | 0.33 |
| ▸ | MAPT | P10636 | 1/20 | 0.33 |
| ▸ | TSHR | P16473 | 1/20 | 0.33 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8098434 | 0.79 | ALDH1A1 (0.34) | KDM4ETSHR | |
| SCHEMBL9518487 | 0.79 | HMGB1 (0.48) | KDM4ELMNATSHR | |
| SCHEMBL9518244 | 0.78 | SHBG (0.40) | KDM4ELMNA | |
| Mivazerol SCHEMBL593708 | 0.78 | PARP1 (0.39) | KDM4EMAPTTSHR | |
| SCHEMBL8089240 | 0.78 | HMGB1 (0.31) | — | |
| Mivazerol SCHEMBL8097939 | 0.78 | PARP1 (0.39) | KDM4EMAPTTSHR | |
| Hydrochloric Acid SCHEMBL10401999 | 0.78 | HMGB1 (0.47) | KDM4ELMNATSHR | |
| SCHEMBL9645443 | 0.77 | MPO (0.38) | KDM4ELMNA | |
| SCHEMBL9647526 | 0.77 | PLK1 (0.38) | KDM4ELMNA | |
| Mivazerol SCHEMBL8865135 | 0.77 | PARP1 (0.38) | KDM4EMAPTTSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0269599-B1 | Substituted 1H-imidazoles | UCB SA (BE) | 1993-12-15 | — | — | EP | claimed |
| US-4814343-A | ANTIISCHEMIC | U C B, S.A. (BE) | 1989-03-21 | — | — | US | claimed |
| EP-0269599-A2 | Substituted 1H-imidazoles | U C B, S.A. (BE) | 1988-06-01 | — | — | EP | claimed |
| EP-0719139-A1 | USE OF CENTRALLY ACTIVE ALPHAAGONISTS FOR INHIBING POSTRAUMATIC METABOLIC STRESS | Dr. Karl Thomae GmbH (DE) | 1996-07-03 | — | — | EP | disclosed |
| WO-1995003798-A2 | USE OF CENTRALLY EFFECTIVE α-2 AGONISTS FOR INHIBITING POSTAGGRESSION METABOLISM | BOEHRINGER INGELHEIM INT (DE) | 1995-02-09 | — | — | WO | disclosed |
| EP-0269599-B1 | Substituted 1H-imidazoles | UCB SA (BE) | 1993-12-15 | — | — | EP | disclosed |
| EP-0341231-B1 | SUBSTITUTED 1-(1H-IMIDAZOL-4-YL)ALKYL BENZAMIDES | U C B, S.A. (BE) | 1992-11-19 | — | — | EP | disclosed |
| US-4923865-A | Substituted 1-(1H-imidazol-4-yl)alkyl-benzamides as anti-ischemics and as alpha-2-adrenergic receptor agonists | U C B SOCIETE ANONYME (BE) | 1990-05-08 | — | — | US | disclosed |
| US-4814343-A | ANTIISCHEMIC | U C B, S.A. (BE) | 1989-03-21 | — | — | US | disclosed |
| EP-0269599-A2 | Substituted 1H-imidazoles | U C B, S.A. (BE) | 1988-06-01 | — | — | EP | disclosed |